MCID: PRG002
MIFTS: 40

Progesterone-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

MalaCards integrated aliases for Progesterone-Receptor Positive Breast Cancer:

Name: Progesterone-Receptor Positive Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060077

Summaries for Progesterone-Receptor Positive Breast Cancer

MalaCards based summary : Progesterone-Receptor Positive Breast Cancer is related to breast cancer and vulvar syringoma. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and lymph node, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Progesterone-Receptor Positive Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 breast cancer 27.5 CYP19A1 ERBB2 ESR1 ESR2 PGR
2 vulvar syringoma 10.4 ESR1 PGR
3 lung leiomyoma 10.4 ESR1 PGR
4 vestibular gland benign neoplasm 10.4 ESR1 PGR
5 bartholin's gland adenoma 10.4 ESR1 PGR
6 vulvar benign neoplasm 10.4 ESR1 PGR
7 trigonitis 10.4 ESR1 PGR
8 vulvar leiomyoma 10.3 ESR1 PGR
9 predominantly cortical thymoma 10.3 ESR1 PGR
10 cribriform carcinoma 10.3 ESR1 PGR
11 endometrial squamous cell carcinoma 10.3 ESR1 PGR
12 gastric signet ring cell adenocarcinoma 10.3 ESR1 PGR
13 benign metastasizing leiomyoma 10.3 CYP19A1 PGR
14 endometrial mucinous adenocarcinoma 10.3 ESR1 PGR
15 adenoid basal cell carcinoma 10.3 ESR1 PGR
16 bartholin's gland benign neoplasm 10.3 ESR1 PGR
17 deep angioma 10.3 ESR1 PGR
18 synchronous bilateral breast carcinoma 10.3 ESR1 PGR
19 cervical carcinosarcoma 10.3 ESR1 PGR
20 intramuscular hemangioma 10.3 ESR1 PGR
21 glycogen-rich clear cell breast carcinoma 10.3 ESR1 PGR
22 retinitis pigmentosa 47 10.3 ESR1 PGR
23 adenomyosis 10.3 ESR1 PGR
24 retinitis pigmentosa 20 10.3 ESR1 PGR
25 endometrial stromal nodule 10.3 CYP19A1 PGR
26 adenosarcoma 10.3 ESR1 PGR
27 cervical clear cell adenocarcinoma 10.3 ESR1 PGR
28 scirrhous adenocarcinoma 10.2 ERBB2 PGR
29 breast apocrine carcinoma 10.2 ERBB2 PGR
30 breast mucoepidermoid carcinoma 10.2 ERBB2 PGR
31 uterine benign neoplasm 10.2 ESR1 PGR
32 breast metaplastic carcinoma 10.2 ERBB2 PGR
33 intracystic papillary adenoma 10.2 ERBB2 PGR
34 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
35 reproductive organ benign neoplasm 10.2 ESR1 PGR
36 smooth muscle tumor 10.2 ESR1 PGR
37 pancreatic mucinous cystadenoma 10.2 ESR1 PGR
38 endometritis 10.2 ESR1 PGR
39 peritoneal mesothelioma 10.2 ESR1 PGR
40 breast squamous cell carcinoma 10.2 ERBB2 PGR
41 endometrial disease 10.2 CYP19A1 ESR1
42 microglandular adenosis 10.2 ERBB2 PGR
43 aromatase deficiency 10.2 CYP19A1 ESR1
44 comedo carcinoma 10.1 ERBB2 ESR1
45 angiomyolipoma 10.1 ESR1 PGR
46 leiomyomatosis 10.1 ESR1 PGR
47 breast secretory carcinoma 10.1 ERBB2 PGR
48 uterine sarcoma 10.1 CYP19A1 ESR1
49 uterine anomalies 10.1 CYP19A1 ESR1
50 primary peritoneal carcinoma 10.0 ERBB2 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to Progesterone-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Positive Breast Cancer

MGI Mouse Phenotypes related to Progesterone-Receptor Positive Breast Cancer:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 PGR ESR1 CYP19A1 ESR2 ERBB2
2 cardiovascular system MP:0005385 9.89 PGR ESR1 CYP19A1 ESR2 ERBB2
3 cellular MP:0005384 9.88 ESR1 CYP19A1 ESR2 ERBB2 PGR
4 endocrine/exocrine gland MP:0005379 9.83 PGR ESR1 CYP19A1 ESR2 ERBB2
5 integument MP:0010771 9.8 ESR1 CYP19A1 ESR2 ERBB2 PGR
6 digestive/alimentary MP:0005381 9.76 ESR1 CYP19A1 ESR2 ERBB2
7 muscle MP:0005369 9.72 ESR1 CYP19A1 ESR2 ERBB2 PGR
8 limbs/digits/tail MP:0005371 9.67 PGR ESR1 ESR2 ERBB2
9 neoplasm MP:0002006 9.56 PGR ESR1 ESR2 ERBB2
10 normal MP:0002873 9.55 ESR1 CYP19A1 ESR2 ERBB2 PGR
11 reproductive system MP:0005389 9.35 ESR1 CYP19A1 ESR2 ERBB2 PGR
12 skeleton MP:0005390 9.02 PGR ESR1 CYP19A1 ESR2 ERBB2

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

Drugs for Progesterone-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Epirubicin Approved Phase 3 56420-45-2 41867
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
7
Anastrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 120511-73-1 2187
8
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198
9
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
10
Tamoxifen Approved Phase 3,Phase 2,Not Applicable 10540-29-1 2733526
11
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-28-2 5757
12 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 979-32-8
13
Fulvestrant Approved, Investigational Phase 3,Phase 2 129453-61-8 104741 17756771
14
Polyestradiol phosphate Approved Phase 3,Phase 2,Not Applicable 28014-46-2
15
Zoledronic acid Approved Phase 3,Phase 2,Not Applicable 118072-93-8 68740
16
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
17
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
18
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
19
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
20
Toremifene Approved, Investigational Phase 2, Phase 3 89778-26-7 3005573
21
Everolimus Approved Phase 3,Phase 2 159351-69-6 6442177
22
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
23
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
24
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
26
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
27
Norepinephrine Approved Phase 3 51-41-2 439260
28
Methyltestosterone Approved Phase 3 58-18-4 6010
29
Testosterone Approved, Investigational Phase 3 58-22-0 6013
30
Testosterone enanthate Approved Phase 3 315-37-7 9416
31
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
32
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
33
Metformin Approved Phase 3 657-24-9 14219 4091
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 77-92-9 311
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
36
Doxil Approved June 1999 Phase 3,Phase 2 31703
37 Alkylating Agents Phase 3,Phase 2
38 Angiogenesis Inhibitors Phase 3,Phase 2
39 Angiogenesis Modulating Agents Phase 3,Phase 2
40 Anti-Bacterial Agents Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 3,Phase 2
42 Antimetabolites Phase 3,Phase 2
43 Antimetabolites, Antineoplastic Phase 3,Phase 2
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2
45 Antirheumatic Agents Phase 3,Phase 2
46 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunosuppressive Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed NCT00050011 Phase 3 Zoledronic Acid;Letrozole
4 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
5 Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients Recruiting NCT02132000 Phase 2, Phase 3 toremifene or tamoxifen
6 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
7 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
8 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3 duloxetine hydrochloride
9 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
10 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
11 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
12 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
13 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
14 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
15 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
16 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
17 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
18 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
19 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
20 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Unknown status NCT01037790 Phase 2 PD-0332991
21 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
22 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
23 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
24 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
25 Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy Completed NCT01160718 Phase 2 fulvestrant;selumetinib
26 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
27 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
28 Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer Completed NCT00755885 Phase 1, Phase 2 abiraterone acetate
29 Phase II Study of Everolimus Beyond Progression Active, not recruiting NCT02269670 Phase 2 everolimus;anastrozole;letrozole;tamoxifen citrate;fulvestrant;megestrol acetate
30 Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus Active, not recruiting NCT02015559 Phase 2 mucoadhesive oral wound rinse
31 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
32 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors Active, not recruiting NCT01831076 Phase 2 Exemestane
33 Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer Terminated NCT00674557 Phase 2 SOD1 inhibitor ATN-224;exemestane
34 Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer Terminated NCT00194792 Phase 2 exemestane;triptorelin pamoate;capecitabine;methotrexate;vinorelbine tartrate;paclitaxel
35 Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain Terminated NCT00892268 Phase 2
36 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
37 Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer Withdrawn NCT00080613 Phase 2 exemestane
38 Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer Withdrawn NCT01013506 Phase 2 IGF-1R inhibitor OSI-906;erlotinib hydrochloride;goserelin;letrozole
39 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
40 BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting NCT01791478 Phase 1 PI3K inhibitor BYL719;letrozole
41 RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer Terminated NCT01208441 Phase 1 letrozole;gamma-secretase/Notch signalling pathway inhibitor RO4929097
42 Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17 Unknown status NCT00897065
43 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Completed NCT00602043 Not Applicable
44 S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer Completed NCT01515800 Not Applicable
45 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
46 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
47 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293 Not Applicable
48 A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Recruiting NCT01824836 Not Applicable anastrozole
49 Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer Recruiting NCT02186470 Not Applicable
50 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

41
Bone, Breast, Lymph Node, Testes, Kidney, Brain, Endothelial

Publications for Progesterone-Receptor Positive Breast Cancer

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show all 20)
# Title Authors Year
1
Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact? ( 29772460 )
2018
2
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. ( 28251385 )
2017
3
Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint. ( 28831439 )
2017
4
Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer. ( 28396965 )
2017
5
Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer. ( 25424702 )
2015
6
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. ( 26363528 )
2015
7
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. ( 26161666 )
2015
8
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. ( 23971947 )
2013
9
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. ( 23579222 )
2013
10
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. ( 23788750 )
2013
11
Progesterone and levonorgestrel regulate expression of 17I^HSD-enzymes in progesterone receptor positive breast cancer cell line T47D. ( 22564730 )
2012
12
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. ( 22548922 )
2012
13
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. ( 20705559 )
2010
14
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. ( 19130322 )
2009
15
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? ( 19703124 )
2009
16
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( 18302747 )
2008
17
Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? ( 17189985 )
2006
18
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. ( 16467123 )
2006
19
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. ( 12408471 )
2002
20
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. ( 9196144 )
1997

Variations for Progesterone-Receptor Positive Breast Cancer

Expression for Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for Progesterone-Receptor Positive Breast Cancer

Pathways related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.41 ERBB2 ESR1 ESR2
2
Show member pathways
12.34 ERBB2 ESR1 ESR2
3
Show member pathways
12.22 ERBB2 ESR1 ESR2 PGR
4
Show member pathways
12.1 ERBB2 ESR1 ESR2
5
Show member pathways
11.87 ERBB2 ESR1 ESR2
6
Show member pathways
11.53 ERBB2 ESR1 PGR
7 11.52 ESR1 ESR2
8
Show member pathways
11.49 ERBB2 ESR1
9
Show member pathways
11.29 ESR1 ESR2 PGR
10 10.9 ESR1 ESR2
11 10.85 ESR1 ESR2
12 10.77 ESR1 ESR2
13 10.64 CYP19A1 ESR2 PGR
14 9.4 CYP19A1 ESR1 ESR2

GO Terms for Progesterone-Receptor Positive Breast Cancer

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA binding transcription factor activity GO:0051091 9.43 ESR1 ESR2
2 phosphatidylinositol phosphorylation GO:0046854 9.4 ERBB2 ESR1
3 mammary gland development GO:0030879 9.37 CYP19A1 PGR
4 intracellular estrogen receptor signaling pathway GO:0030520 9.32 ESR1 ESR2
5 androgen metabolic process GO:0008209 9.26 CYP19A1 ESR1
6 uterus development GO:0060065 9.16 CYP19A1 ESR1
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.13 ESR1 ESR2 PGR
8 steroid hormone mediated signaling pathway GO:0043401 8.8 ESR1 ESR2 PGR

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.71 ERBB2 ESR1 ESR2 PGR
2 sequence-specific DNA binding GO:0043565 9.7 ESR1 ESR2 PGR
3 enzyme binding GO:0019899 9.63 ESR1 ESR2 PGR
4 lipid binding GO:0008289 9.61 ESR1 ESR2 PGR
5 ATPase binding GO:0051117 9.51 ESR1 PGR
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.49 ERBB2 ESR1
7 core promoter sequence-specific DNA binding GO:0001046 9.48 ESR1 ESR2
8 steroid hormone receptor activity GO:0003707 9.43 ESR1 ESR2 PGR
9 estrogen receptor activity GO:0030284 9.37 ESR1 ESR2
10 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
11 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 9.16 ESR1 ESR2
12 nuclear receptor activity GO:0004879 9.13 ESR1 ESR2 PGR
13 steroid binding GO:0005496 8.8 ESR1 ESR2 PGR

Sources for Progesterone-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....